G Taraboletti
Overview
Explore the profile of G Taraboletti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pinessi D, Foglieni C, Bugatti A, Moroni E, Resovi A, Ribatti D, et al.
Thromb Res
. 2016 May;
140 Suppl 1:S182.
PMID: 27161705
Introduction: Platelet thrombospondin-1 (TSP-1) is a major endogenous regulator of growth factor activity in physiological and pathological processes, including tumor onset, progression and angiogenesis. We previously demonstrated that TSP-1 binds...
2.
Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M, et al.
Br J Cancer
. 2007 Sep;
97(7):888-94.
PMID: 17848949
The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies. Scheduling and sequencing remain key issues in the design of VDA-chemotherapy combination treatments. This...
3.
Dolo V, DAscenzo S, Giusti I, Millimaggi D, Taraboletti G, Pavan A
Ital J Anat Embryol
. 2005 Aug;
110(2 Suppl 1):127-33.
PMID: 16101030
Shedding of membrane vesicles is a vital phenomenon frequently observed in tumor cells and suggested to be involved in several aspects of tumor progression. Our previous studies have shown that...
4.
Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Faircloth G, et al.
Br J Cancer
. 2004 Jun;
90(12):2418-24.
PMID: 15173857
The antineoplastic compound aplidine, a new marine-derived depsipeptide, has shown preclinical activity in vitro on haematological and solid tumour cell lines. It is currently in early phase clinical trials. The...
5.
Taraboletti G, Giavazzi R
Eur J Cancer
. 2004 May;
40(6):881-9.
PMID: 15120043
The development of a functional vasculature within a tumour is a requisite for its growth and progression. This fact has led to the design of therapies directed toward the tumour...
6.
Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, et al.
Eur J Cancer
. 2003 Aug;
39(13):1948-56.
PMID: 12932675
We measured the levels of the vascular endothelial growth factor (VEGF), matrix metalloproteinases type 2 and type 9 (MMP-2 and MMP-9) and tissue inhibitors of matrix metalloproteinase 1 and 2...
7.
Broggini M, Marchini S, Galliera E, Borsotti P, Taraboletti G, Erba E, et al.
Leukemia
. 2003 Jan;
17(1):52-9.
PMID: 12529660
The mechanism by which aplidine, a marine natural product in early clinical development as an anticancer agent, induces cell growth inhibition and apoptosis has been investigated in the human leukemia...
8.
9.
Taraboletti G, Margosio B
Curr Opin Pharmacol
. 2001 Nov;
1(4):378-84.
PMID: 11710736
The great interest in the potential antineoplastic effect of targeting tumor-associated blood vessels has generated an expanding armamentarium of therapeutic tools that include antiangiogenic compounds, aimed at preventing the formation...
10.
Vikhanskaya F, Bani M, Borsotti P, Ghilardi C, Ceruti R, Ghisleni G, et al.
Oncogene
. 2001 Nov;
20(50):7293-300.
PMID: 11704858
Tumor neovascularization is controlled by a balance between positive and negative effectors, whose production can be regulated by oncogenes and tumor suppressor genes. The aim of this study was to...